TMS for PTSD is still largely a research treatment. In June 2026 the FDA cleared one TMS-based system, Wave Neuroscience's MeRT System, "as an adjunct for the treatment of adult patients suffering from Post Traumatic Stress Disorder." The standard rTMS protocols used in depression clinics are not cleared for PTSD, so using them for PTSD is off-label.
The research is encouraging but uneven. A European expert guideline rates high-frequency stimulation of the right prefrontal cortex for PTSD as "probable efficacy" (Level B), while a 2026 systematic review of sham-controlled trials found only low-strength evidence that TMS reduces symptom severity and no evidence that it helps people reach remission. Trauma-focused psychotherapy remains the starting point.
The evidence at a glance
PTSD trials differ in target, frequency, coil and whether TMS was paired with therapy, so a single "success rate" would mislead. The table summarizes the studies and guidance that matter most.
| Source | What was tested | What it found |
|---|---|---|
| Lefaucheur et al., European guideline update (2020) | All rTMS literature through 2018 | High-frequency right prefrontal rTMS for PTSD: Level B, "probable efficacy" |
| Systematic review, BMC Psychiatry (2026) | Sham-controlled RCTs in GAD, OCD and PTSD | Low-strength evidence for lower symptom severity; no evidence of benefit for remission |
| Kozel et al., combat veterans (2018) | 1 Hz right prefrontal rTMS just before each cognitive processing therapy session, 103 randomized | Greater PTSD symptom reduction than sham plus therapy, sustained to 6 months |
| Philip et al., veterans (2019) | Intermittent theta burst (iTBS), 50 participants, 10 sham-controlled sessions | Better social and occupational function at 2 weeks; PTSD symptom gains significant only at 1 month, after an unblinded phase |
| Isserles et al., multisite (2021) | Deep TMS of the medial prefrontal cortex after brief trauma-script exposure, 125 randomized | Both groups improved; the active group improved less than sham |
| FDA 510(k) K260402 (2026) | MeRT System, EEG-guided TMS | Cleared as an adjunct for adult PTSD |
Which brain targets have been tried
For depression, cleared TMS targets the left dorsolateral prefrontal cortex. PTSD research has spread across several targets, which is one reason the literature is hard to pool.
- Right dorsolateral prefrontal cortex. This is the target with the most guideline support, at high frequency. The Kozel trial used the same region at low frequency (1 Hz, 1,800 pulses per session).
- Medial prefrontal cortex. This region is involved in fear extinction, the learning that underlies exposure therapy. The Isserles trial stimulated it with a deep TMS H7 coil.
- An individualized frequency. The MeRT System uses a machine-learning algorithm that reads a resting EEG and ECG and sets a personal pulse rate "within the range of 8-13 Hz".
For readers who want the background on coils and frequency, see deep versus standard TMS and how theta burst stimulation works.
Pairing TMS with trauma-focused therapy
The most interesting idea in this field is not TMS alone but TMS timed to therapy: stimulate a circuit, then ask it to learn. The results so far point in opposite directions.
In the Kozel trial, combat veterans received rTMS or sham immediately before weekly cognitive processing therapy for 12 to 15 sessions. The active group had greater reductions on both clinician-rated and self-rated PTSD scales, and the difference held at 6 months. Only 60% of participants completed treatment, and most were men from one era of conflict, which limits how far the result travels.
The Isserles trial tested deep TMS straight after a brief exposure to each patient's trauma narrative, for 12 sessions over 4 weeks. Both groups improved substantially, but the active group improved less than the sham group at 5 weeks and again at 9 weeks. The authors suggested the brief exposure itself may be an effective treatment, and that stimulating this region may have interfered with extinction. That is a useful warning: adding stimulation to therapy is not automatically additive.
A larger, multisite confirmatory trial of 1 Hz right prefrontal rTMS combined with cognitive processing therapy in combat-related PTSD is recruiting, with an estimated 330 participants and completion expected in 2028. Its results should say more than any single small study to date. For an overview of the therapies themselves, see evidence-based trauma treatments and EMDR for PTSD.
What veterans' research adds
Much of the US PTSD work has been done in veterans. Beyond the Kozel trial, the Philip iTBS study in veterans was followed by a one-year naturalistic report: those who had received 4 weeks of active iTBS had longer time to relapse than those who had received 2 weeks, and retreatment with rTMS was generally effective when used. That follow-up was naturalistic rather than blinded.
The VA's experience with TMS for depression is a reminder to stay cautious. In a nine-center VA trial of veterans with treatment-resistant depression, remission was 40.7% with active rTMS and 37.4% with sham, a difference that was not significant. The VA/DoD depression guideline still makes a "weak for" suggestion to offer rTMS after two or more failed medication trials. Coverage for veterans and military families is covered in TMS coverage for veterans, TRICARE and federal employees.
What the 2026 MeRT clearance does and does not mean
The MeRT System was cleared through a 510(k), the same pathway as other TMS devices, with a MagVenture TMS system as its predicate. Wave Neuroscience says the system received Breakthrough Device designation in 2024.
- It is an adjunct, meaning it is intended alongside other PTSD care, not as a replacement for it.
- It is for adults only.
- The clearance covers that specific system and its EEG-guided method. It does not make conventional depression protocols "cleared for PTSD".
- Trial sizes and effect sizes for MeRT circulate in news coverage but were not verifiable in the FDA summary text, so they are left out here.
For how clearance differs from approval, see which TMS devices are FDA-cleared, and for what.
When PTSD and depression occur together
PTSD and major depression often occur together. When someone meets criteria for major depressive disorder that has not responded to medication, TMS for the depression is an on-label use, regardless of the PTSD. In the Philip trial, depression scores also improved with active iTBS at 1 month, in an analysis that included the unblinded phase; at 2 weeks the difference fell short of significance.
Some depression-TMS authorization forms, however, ask the clinician to attest that the patient has no recent OCD or PTSD, which can complicate approval. A psychiatrist can sort out which diagnosis is driving the symptoms and what an honest treatment plan looks like.
If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room. TMS is not an emergency treatment; TMS and suicidal thoughts explains what the research shows.
Safety points specific to PTSD
The general safety profile of TMS applies (see TMS safety and seizure risk). A few points deserve extra attention in people with trauma histories.
- Head injury. FDA guidance asks for close monitoring of patients with a history of head injury, which is relevant for many veterans and assault survivors.
- Sleep and alcohol. The 2021 IFCN safety guideline lists sleep deprivation, increased alcohol use and alcohol withdrawal among factors that lower seizure threshold. Insomnia, nightmares and drinking are common in PTSD and are worth discussing before a course starts.
- Sensory triggers. The clicking coil and the feel of the coil on the head can be activating for some people. A team that knows trauma-informed care can adjust pacing and explanation.
Insurance coverage
Expect TMS for PTSD itself to be uncovered. Aetna lists PTSD among conditions for which TMS is experimental, and Optum lists PTSD among unproven indications. New York Medicare's TMS policy covers adults with confirmed major depressive disorder only. Payer details are in Aetna TMS coverage and UnitedHealthcare and Optum TMS coverage.
The honest bottom line
The 2023 VA/DoD PTSD guideline recommends manualized trauma-focused psychotherapies (prolonged exposure, cognitive processing therapy or EMDR) over medication, and names paroxetine, sertraline and venlafaxine as the recommended drugs. That is where treatment should begin. TMS is a reasonable topic to raise if you have PTSD with treatment-resistant depression, or if you are considering a clinical trial or the newly cleared adjunct device after good-quality therapy has not been enough.
A psychiatrist who knows both trauma care and neuromodulation can help weigh those options. See the TMS physician's guide for the wider evidence base, the TMS service page for how evaluation works, and PTSD treatment options in Brooklyn for the full range of care.
Frequently asked questions
Is TMS FDA-cleared for PTSD?
One system is. In June 2026 the FDA cleared Wave Neuroscience's MeRT System as an adjunct treatment for adults with PTSD. Standard depression TMS protocols used for PTSD remain off-label.
Can TMS replace trauma therapy for PTSD?
No. Trauma-focused psychotherapy such as prolonged exposure, cognitive processing therapy or EMDR is the recommended starting point. TMS is being studied as an add-on, and one trial found that stimulation during brief exposure did worse than sham.
I have PTSD and depression. Could TMS help the depression?
Possibly. If you have major depression that has not improved with medication, TMS for depression is an on-label use. A psychiatrist can assess whether the depression or the PTSD is the main driver of your symptoms.
Does TMS for PTSD bring back traumatic memories?
TMS itself does not deliver memories or images. Some research protocols deliberately pair TMS with recalling a trauma narrative, which is a therapy step, not an effect of the magnetic pulses. Ask exactly what any protocol involves before starting.
Will insurance pay for TMS for PTSD?
Usually not. Aetna lists PTSD as experimental for TMS and Optum lists it as unproven. Coverage is generally limited to major depression and, with some plans, OCD.
Sources
- 510(k) K260402: MeRT System. U.S. FDA, 2026. accessdata.fda.gov
- Wave Neuroscience Announces FDA Clearance of MeRT for PTSD. Wave Neuroscience (press release), 2026. insider.fitt.co
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clinical Neurophysiology, 2020. europepmc.org
- A systematic review of transcranial magnetic stimulation for generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder. BMC Psychiatry, 2026. europepmc.org
- Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. Journal of Affective Disorders, 2018. pubmed.ncbi.nlm.nih.gov
- Theta-Burst Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder. American Journal of Psychiatry, 2019. pubmed.ncbi.nlm.nih.gov
- One-year clinical outcomes following theta burst stimulation for post-traumatic stress disorder. Neuropsychopharmacology, 2020. pubmed.ncbi.nlm.nih.gov
- Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial. Biological Psychiatry, 2021. pubmed.ncbi.nlm.nih.gov
- Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD (NCT03932773). ClinicalTrials.gov, 2026. clinicaltrials.gov
- The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of Internal Medicine, 2024. pubmed.ncbi.nlm.nih.gov
- K231926 510(k) Summary: NeuroStar Advanced Therapy System. U.S. FDA, 2024. accessdata.fda.gov
- Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. JAMA Psychiatry, 2018. pubmed.ncbi.nlm.nih.gov
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. U.S. Department of Veterans Affairs / Department of Defense, 2022. healthquality.va.gov
- Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation (rTMS) Systems. U.S. FDA, 2011. fda.gov
- Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
- Carelon Behavioral Health Repetitive Transcranial Magnetic Stimulation Request Form (commercial contracts). Carelon Behavioral Health, undated. carelonbehavioralhealth.com
- Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (Clinical Policy Bulletin 0469). Aetna, 2026. aetna.com
- Behavioral Clinical Policy: Transcranial Magnetic Stimulation. Optum Behavioral Health Solutions, 2026. providerexpress.com
- LCD L33398 Transcranial Magnetic Stimulation (version 40). CMS Medicare Coverage Database, 2026. cms.gov
Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel